Porsche Cars North America today officially opened its new $100 million Porsche Experience Center (PEC) and headquarters in Atlanta, Georgia. The 27-acre complex located at the Northeast corner of Hartsfield-Jackson Atlanta International Airport is the largest investment outside Germany for the sports car manufacturer. The industry-first facility is complete with a driver development track, classic car gallery, restoration center, human performance center and driving simulator lab. A state-of-the-art business center features 13,000 square feet of conference and event space and a fine dining restaurant. The experience center has been specifically designed as a destination for the public, including automotive enthusiasts and Porsche customers.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7477151-100-million-porsche-experience-center/
Greater Fort Lauderdale/Broward County is in the midst of unprecedented economic development, with new research revealing an influx of affluent visitors as the driving force behind new travel and hospitality-related construction and investment.
The average annual income of domestic travelers to the destination has reached $112,563 – almost 25% higher than the national average, according to a comprehensive analysis of the domestic travel market in the United States by research firm D. K. Shifflet & Associates Ltd., commissioned by the Greater Fort Lauderdale Convention & Visitors Bureau.
That is a dramatic 15.5% increase from the destination’s average in 2012 of $97,517, placing Greater Fort Lauderdale among the top leisure destinations in the U.S., and well above the national average visitor income of $90,591.
This increasing appeal to affluent travelers has led to a record-breaking 14.3 million tourists spending $11.4 billion annually in the destination, which is situated along Florida’s famed Atlantic Ocean coastline between Miami and Palm Beach.
To view the multimedia release go to:
http://www.multivu.com/players/English/7640751-greater-fort-lauderdale-development-boom/
Today, Novo Nordisk announced new phase 3 interim data from its guardianTM2 trial for its recombinant coagulation factor VIII (rFVIII) product NovoEight® (turoctocog alfa), the first new rFVIII molecule in over a decade, which shows that it provides long-term reduction from bleeding in people with haemophilia A when used as a preventative treatment.1 The results were presented at the World Federation of Haemophilia (WFH) World Congress and support findings from other studies within the guardianTM clinical programme that found NovoEight® demonstrated good efficacy in preventing and treating bleeds without inhibitor development in previously treated patients.
To view the Multimedia News Release, go to: http://www.multivu.com/mnr/71400529-novoeight-reduction-of-bleeding-haemophilia-a
FileMaker today announced a new version of its development platform that speeds creation of custom solutions that run on iPad, iPhone, Windows, Mac and the web. FileMaker 14 brings point-and-click simplicity to automating business processes, delivering desktop-style application functionality to mobile web browsers and providing productive, engaging experiences on desktops, iOS devices and mobile web browsers.
The announcement coincides with the 30th anniversary of FileMaker software. FileMaker was the brainchild of a bootstrapped startup founded in Massachusetts by four entrepreneurs intent on creating easy-to-use database software.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7318353-filemaker-platform-14/
Early findings from a major research initiative of the Crohn’s & Colitis Foundation of America (CCFA) suggest that specific bacteria play a central role in Crohn’s disease and ulcerative colitis (UC), also known as inflammatory bowel diseases (IBD). The evidence raises the possibility of developing new treatments to target the gut microbiome—the “ecosystem” of microbes populating the intestines—linked to the development of IBD.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7204351-crohn-s-colitis-foundation-of-america-gut-bacteria-new-strategies-to-prevent/
As part of an ongoing commitment to support life sciences innovators and the development of integrated, cross-sector solutions to prevent, intercept and cure diseases, Johnson & Johnson today named cell biologist Yoshinori Ohsumi, Ph.D., of the Tokyo Institute of Technology the winner of the 2016 Dr. Paul Janssen Award for Biomedical Research for his pioneering discoveries concerning the molecular basis of autophagy.
Dr. Ohsumi was honored today during an event at the 2016 BIO International Convention in San Francisco. A video of his acceptance comments can be viewed here.
“Dr. Ohsumi’s curiosity led him to become the first person in the world to determine the molecular mechanism and regulation of autophagy, shedding light on one of the most basic functions of all living cells,” said Paul Stoffels, M.D., Chief Scientific Officer, Johnson & Johnson. “Dr. Ohsumi’s discoveries hold promise for better understanding, preventing and treating many diseases. It is with great pleasure that we celebrate his contributions, which remind us of the innovative spirit Dr. Paul brought to the lab every day.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7856351-2016-dr-paul-janssen-award-ohsumi/
Last weekend, OUE hosted the official grand opening of OUE Skyspace LA. Guests flocked from near and far to be among the first to experience the public debut of California’s tallest open-air observation deck and Skyslide with a slew of celebratory events throughout the weekend.
On Friday, June 24, the ribbon-cutting ceremony hosted local and international VIPs as OUE Skyspace LA opened its doors for the very first time. Speakers included Dr. Stephen Riady, Executive Chairman of OUE and Raymond Chan, Interim Deputy Mayor for Economic Development. Following the ribbon-cutting ceremony, an evening of special performances from artists such as Brian McKnight, and more wowed OUE’s guests of honor.
To view the multimedia release go to:
http://www.multivu.com/players/English/7856151-oue-skyspace-los-angeles-launch/
Kushion.com, launches today featuring Kushion the first true Bluetooth Speaker Pillow that will enhance several aspects of your life. Connect to your phone for hands free talking, charge your phone and still keep the whole house thumpin' with home theater quality speakers all in your pillow. This multi-functional next generation “Boom Box” enhances the experience in your bedroom, hotel room, living room, dorm room also great for tailgating and gaming…. practically anywhere.
“After 2 years of development the Kushion has arrived, taking pillow talk and after parties to new heights,” says David Fuchs of Kushion.com. And it charges your phone!
To view the multimedia release go to:
http://www.multivu.com/players/English/7909051-kushion-bluetooth-speaker-pillow/
Newron Pharmaceuticals S.p.A. (“Newron”), a research and development company focused on novel CNS and pain therapies, and its partner Zambon S.p.A., an international pharmaceutical company strongly committed to the CNS therapeutic area, announced today that the EU Committee for Medicinal Pro-ducts for Human Use (CHMP) recommended that the European Commission approve the use of Xadago™ (safinamide) as add-on to L-dopa alone or in combination with dopamine agonists, entacapone, amantadine, and/or anticholinergics, for the treatment of patients with mid-late stage Parkinson’s disease experiencing motor fluctuations despite being stabilized on ‘Standard of Care’.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7406951-chmp-xadago-parkinsons/
Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced today that many retina specialists throughout the U.S. are now using ILUVIEN® (fluocinolone acetonide intravitreal implant) 0.19 mg to treat patients with diabetic macular edema (DME). The first injections of ILUVIEN in the U.S. were captured during a live web event attended by more than 250 eye care professionals. ILUVIEN is the first multiyear eye implant designed to deliver a continuous, submicrogram daily dose of steroid to the retina for 36 months with one injection. ILUVIEN is indicated for the treatment of DME in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure (IOP).
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7496251-iluvien-dme/
Centennial graduate Stephanie Matzos shares her thoughts on College and her position at The Children's Wish Foundation of Canada. Find out more about Alumni Association at http://www.centennialcollege.ca/student-services/clubs-associations/alumni-development/alumni.aspx
Positive strides have been made since 1995 to advance science literacy in the United States, but teachers and parents agree that more hands-on, experiential learning must be adopted in order to improve science education for future generations, according to the results of the 2015 Bayer Facts of Science Education Survey released today.
For 20 years, Bayer has issued the survey, which assesses science education in the United States and evaluates its development. Although positive strides have been made, survey results emphasize the critical need to improve science education and literacy for future generations. Teachers, for example, universally agree (99 percent) that more hands-on experiential learning in general would benefit student learning.
In response, Bayer is announcing a five-year commitment to provide 1 million hands-on science learning experiences for children by 2020, timed to the 20th anniversary of the Making Science Make Sense® program, Bayer’s company-wide initiative that advances science literacy across the United States.
To view the multimedia release go to:
http://www.multivu.com/players/English/7452954-bayer-children-science-education/
